Straits Times Index
3,284.67 -8.46 (-0.26%) Nikkei
37,628.48 -831.60 (-2.16%) Hang Seng
17,260.57 +59.30 (+0.34%) FTSE 100
8,077.47 +37.09 (+0.46%) Bitcoin USD
63,914.80 -2,758.76 (-4.14%) CMC Crypto 200
1,389.12 +6.55 (+0.47%)
Endo International plc (ENDPQ)
| Previous close | 0.0006 |
| Open | 0.0007 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0006 - 0.0007 |
| 52-week range | 0.0001 - 0.0800 |
| Volume | |
| Avg. volume | 119,098 |
| Market cap | 141,132 |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.4100 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePar Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product solution.
CNW GroupEndo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
ReutersDrugmaker Endo receives US court approval for bankruptcy restructuring
As part of the bankruptcy plan, over 95% of the company's ownership will be handed over to its lender group, which includes investment firms Oaktree Capital Management, Silver Point Capital and Bain Capital. Endo had last month agreed to pay up to $465 million over a decade to resolve over $7 billion in claims for purported tax debts, a criminal investigation into the company's opioid marketing and the federal government's possible overpayment for its medications. Endo filed for bankruptcy in August 2022 to address its $8 billion debt and thousands of lawsuits over its alleged role in the U.S. opioid epidemic.
